The Postpartum Depression Drug market is estimated to be valued at US$ 5.115 Billion In 2022 and is expected to exhibit a CAGR of 30.25% over the forecast period 2022-2029, as highlighted in a new report published by Coherent Market Insights.
Postpartum depression drug market comprises antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other antidepressants that are used for the treatment of postpartum depression. Postpartum depression is a mood disorder that is commonly experienced after childbirth.
The postpartum depression drug market is primarily driven by the increasing incidence of postpartum depression worldwide. According to World Health Organization (WHO), postpartum depression affects approximately 13% of women globally after childbirth. Furthermore, emerging therapies for postpartum depression such as esketamine nasal spray and brexanolone intravenous infusion are expected to offer new treatment options, thereby supporting the market growth over the forecast period.
There is a rising awareness about mental health issues like postpartum depression among women. With more women openly sharing their experiences on social media and through support groups, the social stigma around postpartum depression is reducing. This is encouraging more women to seek timely diagnosis and treatment for postpartum depression. Moreover, with growing scientific evidence proving the effectiveness of pharmacological interventions for postpartum depression, more women and doctors are willing to consider prescription medication as a treatment option.
Strengths: The Postpartum Depression Drug Market has strong growth potential due to the high prevalence of postpartum depression among new mothers.
Weaknesses: Side effects of existing drug therapies like weight gain, sleep problems, and sexual dysfunction act as barriers in treatment compliance.
Opportunities: Launch of novel drugs with improved safety profiles can cater to unmet needs and drive market growth. Growing awareness can increase the diagnosis and treatment rates over the forecast period.
Threats: Stringent regulatory frameworks for the approval of postpartum depression drugs and long drug development cycles are challenges for market players.
The global Postpartum Depression Drug market is expected to witness high growth at a CAGR of 30.25% over the forecast period of 2022-2029. The market was valued at US$ 5.115 Billion In 2021.
Regional analysis: North America dominated the global market in 2021 due to early adoption of medications for postpartum depression. However, Asia Pacific is anticipated to be the fastest growing market over the forecast period supported by improving healthcare access and growing middle-class population in countries like China and India.
Key players: Key players operating in the postpartum depression drug market are Sage Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Intas Pharmaceuticals Ltd., Mylan N.V., Anikem Laboratories, and Shionogi & Co., Ltd. Sage Therapeutics Inc. holds a leading market position owing to its novel drug Zulresso approved for severe postpartum depression.
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it